Cannabidiol (CBD) (INN) is one of at least 113 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. CBD is considered to have a wide scope of potential medical applications - due to clinical reports showing the lack of side effects, particularly a lack of psychoactivity (as is typically associated with ∆9-THC).
- government licensed operation
- all products are made from legal EU hemp varieties
- a guarantee of natural phytocannabinoid content
This is an updated version (January 2017) of the position paper of the European Industrial Hemp Association (EIHA) on reasonable regulation of cannabidiol (CBD) in food, cosmetics, as herbal natural medicine and as medicinal product, first published in October 2016.
2017: Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
In this context, the related nonpsychotropic cannabinoid cannabidiol, which may interact with the endocannabinoid system but has actions that are distinct, offers promise as a prototype for anti-inflammatory drug development.
2017: The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
These findings support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signalling.